Next Article in Journal
Smoking and SARS-CoV-2 Disease (COVID-19): Dangerous Liaisons or Confusing Relationships?
Next Article in Special Issue
Prognostic Value of Growth Differentiation Factor 15 in Kidney Donors and Recipients
Previous Article in Journal
Right Ventricular Free Wall Strain and Congestive Hepatopathy in Patients with Acute Worsening of Chronic Heart Failure: A CATSTAT-HF Echo Substudy
Previous Article in Special Issue
Group IIA Secretory Phospholipase A2 Predicts Graft Failure and Mortality in Renal Transplant Recipients by Mediating Decreased Kidney Function
 
 
Article

Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation

1
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea
2
Statistics and Data Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul 06355, Korea
*
Authors to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(5), 1320; https://doi.org/10.3390/jcm9051320
Received: 14 April 2020 / Revised: 28 April 2020 / Accepted: 29 April 2020 / Published: 2 May 2020
(This article belongs to the Special Issue Clinical Complications after Kidney Transplantation)
The objective of this study was to compare outcomes between basiliximab and low-dose r-ATG in living donor kidney transplantation recipients with low immunological risk. Patients in the low-dose r-ATG group received 1.5 mg/kg of r-ATG for 3 days (total 4.5 mg/kg). Graft survival, patient survival, acute rejection, de novo donor specific antibody (DSA), estimated glomerular filtration rate (e-GFR) changes, and infection status were compared. Among 268 patients, 37 received r-ATG, and 231 received basiliximab. There was no noticeable difference in the graft failure rate (r-ATG vs. basiliximab: 2.7% vs. 4.8%) or rejection (51.4% vs. 45.9%). de novo DSA was more frequent in the r-ATG group (11.4% vs. 2.4%, p = 0.017). e-GFR changes did not differ noticeably between groups. Although most infections showed no noticeable differences between groups, more patients in the r-ATG group had cytomegalovirus (CMV) antigenemia and serum polyomavirus (BK virus) (73.0% vs. 51.9%, p = 0.032 in CMV; 37.8% vs. 15.6%, p = 0.002 in BK), which did not aggravate graft failure. Living donor kidney transplantation patients who received low-dose r-ATG and patients who received basiliximab showed comparable outcomes in terms of graft survival, function, and overall infections. Although CMV antigenemia, BK viremia were more frequent in the r-ATG group, those factors didn’t change the graft outcomes. View Full-Text
Keywords: basiliximab; rabbit anti-thymocyte globulin; graft survival; kidney transplantation basiliximab; rabbit anti-thymocyte globulin; graft survival; kidney transplantation
Show Figures

Figure 1

MDPI and ACS Style

Kim, S.J.; Rhu, J.; Yoo, H.; Kim, K.; Lee, K.W.; Park, J.B. Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation. J. Clin. Med. 2020, 9, 1320. https://doi.org/10.3390/jcm9051320

AMA Style

Kim SJ, Rhu J, Yoo H, Kim K, Lee KW, Park JB. Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation. Journal of Clinical Medicine. 2020; 9(5):1320. https://doi.org/10.3390/jcm9051320

Chicago/Turabian Style

Kim, Sang Jin, Jinsoo Rhu, Heejin Yoo, Kyunga Kim, Kyo Won Lee, and Jae Berm Park. 2020. "Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation" Journal of Clinical Medicine 9, no. 5: 1320. https://doi.org/10.3390/jcm9051320

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop